J
Julian Sikorski
Publications - 7
Citations - 2451
Julian Sikorski is an academic researcher. The author has contributed to research in topics: Immune system & Antibody. The author has an hindex of 6, co-authored 7 publications receiving 1033 citations.
Papers
More filters
Journal ArticleDOI
COVID-19 vaccine BNT162b1 elicits human antibody and T H 1 T cell responses.
Ugur Sahin,Alexander Muik,Evelyna Derhovanessian,Isabel Vogler,Lena M. Kranz,Mathias Vormehr,Alina Baum,Kristen E. Pascal,Jasmin Quandt,Daniel Maurus,Sebastian Brachtendorf,Verena Lörks,Julian Sikorski,Rolf Hilker,Dirk Becker,Ann Kathrin Eller,Jan Grützner,Carsten Boesler,Corinna Rosenbaum,Marie Cristine Kühnle,Ulrich Luxemburger,Alexandra Kemmer-Brück,David J. Langer,Martin Bexon,Stefanie Bolte,Katalin Karikó,Tania Palanche,Boris Fischer,Armin Schultz,Pei Yong Shi,Camila R. Fontes-Garfias,John L. Perez,Kena A. Swanson,Jakob Loschko,Ingrid L. Scully,Mark Cutler,Warren Kalina,Christos A. Kyratsous,David A. Cooper,Philip R. Dormitzer,Kathrin U. Jansen,Özlem Türeci +41 more
TL;DR: The robust RBD-specific antibody, T cell and favourable cytokine responses induced by the BNT162b1 mRNA vaccine suggest that it has the potential to protect against COVID-19 through multiple beneficial mechanisms.
Journal ArticleDOI
BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans.
Ugur Sahin,Alexander Muik,Isabel Vogler,Evelyna Derhovanessian,Lena M. Kranz,Mathias Vormehr,Jasmin Quandt,Nicole Bidmon,Alexander Ulges,Alina Baum,Kristen E. Pascal,Daniel Maurus,Sebastian Brachtendorf,Verena Lörks,Julian Sikorski,Peter Koch,Rolf Hilker,Dirk Becker,Ann Kathrin Eller,Jan Grützner,Manuel Tonigold,Carsten Boesler,Corinna Rosenbaum,Ludwig Heesen,Marie Cristine Kühnle,Asaf Poran,Jesse Z. Dong,Ulrich Luxemburger,Alexandra Kemmer-Brück,David J. Langer,Martin Bexon,Stefanie Bolte,Tania Palanche,Armin Schultz,Sybille Baumann,Azita J. Mahiny,Gábor Boros,Jonas Reinholz,Gábor Szabó,Katalin Karikó,Pei Yong Shi,Camila R. Fontes-Garfias,John L. Perez,Mark Cutler,David A. Cooper,Christos A. Kyratsous,Philip R. Dormitzer,Kathrin U. Jansen,Özlem Türeci +48 more
TL;DR: BNT162b2, a lipid nanoparticle (LNP) formulated nucleoside-modified messenger RNA (mRNA) that encodes the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) spike glycoprotein (S) stabilized in the prefusion conformation, has demonstrated 95% efficacy in preventing coronavalirus disease-19 (COVID-19)1 as mentioned in this paper.
Journal ArticleDOI
An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma.
Ugur Sahin,Petra Oehm,Evelyna Derhovanessian,Robert A. Jabulowsky,Mathias Vormehr,Maike Gold,Daniel Maurus,Doreen Schwarck-Kokarakis,Andreas Kuhn,Tana Omokoko,Lena M. Kranz,Mustafa Diken,Sebastian Kreiter,Heinrich Haas,Sebastian Attig,Richard Rae,Katarina Cuk,Alexandra Kemmer-Brück,Andrea Breitkreuz,Claudia Tolliver,Janina Caspar,Juliane Quinkhardt,Lisa Hebich,Malte Stein,Alexander Hohberger,Isabel Vogler,Inga Liebig,Stephanie Renken,Julian Sikorski,Melanie Leierer,Verena Müller,Heidrun Mitzel-Rink,Matthias Miederer,Christoph Huber,Stephan Grabbe,Jochen Utikal,Andreas Pinter,Roland Kaufmann,Jessica C. Hassel,Carmen Loquai,Özlem Türeci +40 more
TL;DR: Results of an exploratory interim analysis from a phase I trial show that an RNA vaccine targeted towards four melanoma-associated antigens produces durable objective responses in patients with melanoma that are accompanied by strong CD4 + and CD8 + T-cell immunity.
Posted ContentDOI
BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans
Ugur Sahin,Alexander Muik,Isabel Vogler,Evelyna Derhovanessian,Lena M. Kranz,Mathias Vormehr,Jasmin Quandt,Nicole Bidmon,Alexander Ulges,Alina Baum,Kristen E. Pascal,Daniel Maurus,Sebastian Brachtendorf,Verena L Loerks,Julian Sikorski,Peter Koch,Rolf Hilker,Dirk Becker,Ann-Kathrin Eller,Jan Gruetzner,Manuel Tonigold,Carsten Boesler,Corinna Rosenbaum,Ludwig Heesen,Marie-Cristine Kuehnle,Asaf Poran,Jesse Z. Dong,Ulrich Luxemburger,Alexandra Kemmer-Brueck,David J. Langer,Martin Bexon,Stefanie Bolte,Tania Palanche,Armin Schultz,Sybille Baumann,Azita J. Mahiny,Gábor Boros,Jonas Reinholz,Gabor T Szabo,Katalin Karikó,Pei Yong Shi,Camila R. Fontes-Garfias,John L. Perez,Mark Cutler,David A. Cooper,Christos A. Kyratsous,Philip R. Dormitzer,Kathrin U. Jansen,Oezlem Tuereci +48 more
TL;DR: Vaccination with BNT162b2 at well tolerated doses elicits a combined adaptive humoral and cellular immune response, which together may contribute to protection against COVID-19.
Posted ContentDOI
Concurrent human antibody andTH1 type T-cell responses elicited by a COVID-19 RNA vaccine
Ugur Sahin,Alexander Muik,Evelyna Derhovanessian,Isabel Vogler,Lena M. Kranz,Mathias Vormehr,Alina Baum,Kristen E. Pascal,Jasmin Quandt,Daniel Maurus,Sebastian Brachtendorf,Verena L Loerks,Julian Sikorski,Rolf Hilker,Dirk Becker,Ann-Kathrin Eller,Jan Gruetzner,Carsten Boesler,Corinna Rosenbaum,Marie-Cristine Kuehnle,Ulrich Luxemburger,Alexandra Kemmer-Brueck,David J. Langer,Martin Bexon,Stefanie Bolte,Katalin Karikó,Tania Palanche,Boris Fischer,Armin Schultz,Pei Yong Shi,Camila R. Fontes-Garfias,John L. Perez,Kena A. Swanson,Jakob Loschko,Ingrid L. Scully,Mark Cutler,Warren Kalina,Christos A. Kyratsous,David A. Cooper,Philip R. Dormitzer,Kathrin U. Jansen,Oezlem Tuereci +41 more
TL;DR: The robust RBD-specific antibody, T-cell and favourable cytokine responses induced by the BNT162b1 mRNA vaccine suggest multiple beneficial mechanisms with potential to protect against COVID-19.